Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y, Carrascosa LC, Yeung YA, Chu ML, Yang W, Djuretic I, Pappas DC, Zeytounian J, Ge Z, de Ruiter V, Starbeck-Miller GR, Patterson J, Rigas D, Chen SH, Kraynov E, Boor PP, Noordam L, Doukas M, Tsao D, Ijzermans JN, Guo J, Grünhagen DJ, Erdmann J, Verheij J, van Royen ME, Doornebosch PG, Feldman R, Park T, Mahmoudi S, Dorywalska M, Ni I, Chin SM, Mistry T, Mosyak L, Lin L, Ching KA, Lindquist KC, Ji C, Londono LM, Kuang B, Rickert R, Kwekkeboom J, Sprengers D, Huang TH, Chaparro-Riggers J. Xu Y, et al. Among authors: ching ka. Cancer Immunol Res. 2021 Oct;9(10):1141-1157. doi: 10.1158/2326-6066.CIR-21-0058. Epub 2021 Aug 10. Cancer Immunol Res. 2021. PMID: 34376502
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Campos Carrascosa L, van Beek AA, de Ruiter V, Doukas M, Wei J, Fisher TS, Ching K, Yang W, van Loon K, Boor PPC, Rakké YS, Noordam L, Doornebosch P, Grünhagen D, Verhoef K, Polak WG, IJzermans JNM, Ni I, Yeung YA, Salek-Ardakani S, Sprengers D, Kwekkeboom J. Campos Carrascosa L, et al. J Immunother Cancer. 2020 Sep;8(2):e000816. doi: 10.1136/jitc-2020-000816. J Immunother Cancer. 2020. PMID: 32900860 Free PMC article.
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.
Park YH, Lal S, Lee JE, Choi YL, Wen J, Ram S, Ding Y, Lee SH, Powell E, Lee SK, Yu JH, Ching KA, Nam JY, Kim SW, Nam SJ, Kim JY, Cho SY, Park S, Kim J, Hwang S, Kim YJ, Bonato V, Fernandez D, Deng S, Wang S, Shin H, Kang ES, Park WY, Rejto PA, Bienkowska J, Kan Z. Park YH, et al. Among authors: ching ka. Nat Commun. 2020 Dec 2;11(1):6175. doi: 10.1038/s41467-020-19933-0. Nat Commun. 2020. PMID: 33268821 Free PMC article.
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas.
Gopal AK, Levy R, Houot R, Patel SP, Popplewell L, Jacobson C, Mu XJ, Deng S, Ching KA, Chen Y, Davis CB, Huang B, Fly KD, Thall A, Woolfson A, Bartlett NL. Gopal AK, et al. Among authors: ching ka. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534. doi: 10.1158/1078-0432.CCR-19-2973. Epub 2020 Mar 6. Clin Cancer Res. 2020. PMID: 32144134 Clinical Trial.
37 results